Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
- Significant progress in PREVENT-19 study; final data expected in the second quarter of 2021
- Initiated pediatric extension of PREVENT-19 in the U.S.
- Evaluating COVID-19 booster performance in U.S. and Australia Phase 2 and South Africa Phase 2b studies, as well as study with the University of Oxford
- Finalized APA with Gavi to supply 1.1 billion doses for the COVAX Facility
- Company to host conference call today at 4:30 p.m. ET
News provided by
Share this article
Share this article
GAITHERSBURG, Md., May 10, 2021 /PRNewswire/ Novavax, Inc. (NASDAQ: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2021.
1/24/21
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE)
Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of
Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies to assess the company’s operational performance, including areas related to portfolio valuation, milestone decision making and prioritization. She will report directly to
Stanley C. Erck, President and Chief Executive Officer.
“Lyn’s deep experience in managing complex global programs will be critical as we work to simultaneously advance NVX-CoV2373 regulatory activities forward in multiple regions,” said Mr. Erck. “We welcome her invaluable project management exper
Novavax Names Madelyn Caltabiano Senior Vice President, Global Program Management
January 22, 2021 16:49 ET | Source: Novavax, Inc. Novavax, Inc. Gaithersburg, Maryland, UNITED STATES
GAITHERSBURG, Md., Jan. 22, 2021 (GLOBE NEWSWIRE) Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the appointment of Madelyn ‘Lyn’ Caltabiano, Ph.D. to the position of Senior Vice President, Global Program Management. In this newly created role, Dr. Caltabiano will lead and expand the Global Program Management organization for the company’s pipeline and will develop appropriate strategies to assess the company’s operational performance, including areas related to portfolio valuation, milestone decision making and prioritization. She will report directly to Stanley C. Erck, President and Chief Executive Officer.